Assessing the long-term impact of treating Hepatitis C Virus (HCV)-infected people who inject drugs in the UK and the relationship between treatment uptake and efficacy on future infections

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Bennett, Hayley ^a   McEwan, Phil ^a,b   Sugrue, Daniel ^a   Kalsekar, Anupama ^c   Yuan, Yong ^c  

^a HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c Global Health Economics and Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEPATITIS C; ARTICLE; CHRONIC HEPATITIS C; COST CONTROL; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; INTRAVENOUS DRUG ABUSE; LIVER CANCER; LIVER TRANSPLANTATION; MORTALITY; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; UNITED KINGDOM; VIRUS TRANSMISSION; COMPLICATION; ECONOMICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; PHYSIOLOGY; SUBSTANCE ABUSE; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84929104041     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125846     Document Type: Article

References (49)

1. Hellard M, Sacks-Davis R, Gold J (2009) Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 49: 561-573. doi: 10.1086/600304 PMID: 19589081
2. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. (2013) Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58: 1598-1609. doi: 10.1002/hep.26431 PMID: 23553643
3. Corson S, Greenhalgh D, Hutchinson S (2012) Mathematically modelling the spread of hepatitis C in injecting drug users. Math Med Biol 29: 205-230. doi: 10.1093/imammb/dqr011 PMID: 21900152
4. Hutchinson SJ, Bird SM, Taylor A, Goldberg DJ (2006) Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention. Int J Drug Policy 17: 211-221.
5. Vickerman P, Martin N, Turner K, Hickman M (2012) Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107: 1984-1995. doi: 10.1111/j.1360-0443.2012.03932.x PMID: 22564041
6. University of the West of Scotland. The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among people who inject drugs attending injecting provision services in Scotland, 2008/2009 & 2010. Available: http://www.documents.hps.scot.nhs.uk/bbvsti/hepatitis-c/publications/nesi-needle-exchange.pdf. Accessed 2014 Mar 1.
7. Public Health England. Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs. Available: http://webarchive.nationalarchives.gov.uk/20140629102627/ http:/hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb-C/1202115519183. Accessed 2015 Feb 1.
8. Public Health England. Hepatitis C in the UK: 2013 report Available: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/364074/Hepatitis-C-in-the-UK-2013.pdf. Accessed 2015 Feb 1.
9. The All-Party Parliamentary Hepatology Group. In the Dark: An audit of hospital hepatitis C services across England. Available: http://www.appghep.org.uk/reports/in-the-dark-an-audit-of-hospital-hepatitis-c-services-across-england-apphg-2010/. Accessed 2015 Feb 1.
10. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, HickmanM (2011) Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 54: 1137-1144. doi: 10.1016/j.jhep.2010.08.029 PMID: 21145810
11. Dore GJ (2012) The changing therapeutic landscape for hepatitis C. Med J Aust 196: 629-632. PMID: 22676877
12. Hay G, Gannon M, McKeganey N, Hutchinson S, Goldberg D (2004) Estimating the national and local prevalence of problem drug misuse in Scotland: University of Glasgow, Centre for Drug Misuse Research.
13. Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, et al. (2009) Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol 170: 352-360. doi: 10.1093/aje/kwp141 PMID: 19546152
14. Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. (2010) Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 341: c3172. doi: 10.1136/bmj.c3172 PMID: 20595255
15. Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, et al. (2009) Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health 31: 374-382.
16. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M (2010) Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 341.
17. Health Protection Scotland and University of the West of Scotland. Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV, HIV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2007. Available: http://www.hps.scot.nhs.uk/search/atozdetail.aspx?source=8&subject=93. Accessed 2014 Mar 1.
18. Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A (2012) Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy 23: 346-352. doi: 10.1016/j.drugpo.2012.07.006 PMID: 22940142
19. Kemp PA, Neale J, Robertson M (2006) Homelessness among problem drug users: prevalence, risk factors and trigger events. Health Soc Care Community 14: 319-328. PMID: 16787483
20. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, et al. (2012) Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol 24: 646-655. doi: 10.1097/MEG.0b013e32835201a4 PMID: 22433796
21. Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepatitis 13: 34-41. PMID: 16364080
22. Mondelli MU, Cerino A, Cividini A (2005) Acute hepatitis C: diagnosis and management. J Hepatol 42: S108-S114. PMID: 15777565
23. Turner KME, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106: 1978-1988. doi: 10.1111/j.1360-0443.2011.03515.x PMID: 21615585
24. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. (2013) Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 57: S80-S89. doi: 10.1093/cid/cit306 PMID: 23884071
25. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206. doi: 10.1056/NEJMoa1010494 PMID: 21449783
26. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416. doi: 10.1056/NEJMoa1012912 PMID: 21696307
27. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44. doi: 10.1056/NEJMoa1208953 PMID: 23281974
28. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. (2013) Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368: 45-53. doi: 10.1056/NEJMoa1208809 PMID: 23281975
29. National Institute for Health and Care Excellence. Technology Appraisal TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. Available: http://guidance.nice.org.uk/TA106. Accessed 2014 Mar 1.
30. McEwan P, Kim R, Yuan Y (2013) Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model. Appl Health Econ Health Policy 11: 53-63. doi: 10.1007/s40258-012-0002-0 PMID: 23329380
31. McEwan P, Ward T, Yuan Y, Kim R, L'Italien G (2013) The impact of timing and prioritization on the cost?effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 58: 54-64. doi: 10.1002/hep.26304 PMID: 23389841
32. McEwan P, Ward T, Chen C-J, Lee M-H, Yang H-I, Kim R, et al. (2013) Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. Value in Health Regional Issues 3: 5-11.
33. Martin NK, Vickerman P, Hickman M (2011) Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 274: 58-66. doi: 10.1016/j.jtbi.2010.12.041 PMID: 21236265
34. Zeiler I, Langlands T, Murray JM, Ritter A (2010) Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 110: 228-233. doi: 10.1016/j.drugalcdep.2010.03.006 PMID: 20430537
35. Vickerman P, Martin N, Hickman M (2011) Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend 113: 83-85. doi: 10.1016/j.drugalcdep.2010.08.001 PMID: 20832198
36. Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, et al. (2012) Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 196: 638. PMID: 22676879
37. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P (2013) Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57: S39-S45. doi: 10.1093/cid/cit296 PMID: 23884064
38. Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E (2014) Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology 59: 366-369. doi: 10.1002/hep.26623 PMID: 23873507
39. Hallinan R, Byrne A, Agho K, Dore GJ (2007) Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 88: 49-53. PMID: 17067763
40. Lindenburg CEA, Lambers FAE, Urbanus AT, Schinkel J, Jansen PLM, Krol A, et al. (2011) Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 23: 23-31. doi: 10.1097/MEG.0b013e328340c451 PMID: 21042221
41. Harris KA Jr, Arnsten JH, Litwin AH (2010) Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 4: 20. doi: 10.1097/ADM.0b013e3181add3de PMID: 20485532
42. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. (2010) Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 22: 270-277. PMID: 20425880
43. Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy K, Hassanein T, et al. (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 370: 211-221. doi: 10.1056/NEJMoa1306218 PMID: 24428467
44. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C-Y, et al. (2014) All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384: 1597-1605. doi: 10.1016/S0140-6736(14)61059-X PMID: 25078304
45. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889-1898. doi: 10.1056/NEJMoa1402454 PMID: 24725239
46. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867-1877. doi: 10.1056/NEJMoa1214854 PMID: 23607593
47. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368: 1878-1887. doi: 10.1056/NEJMoa1214853 PMID: 23607594
48. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594-1603. doi: 10.1056/NEJMoa1315722 PMID: 24720703
49. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH (2013) Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 56: 806-816. doi: 10.1093/cid/cis1007 PMID: 23223596